Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
TC BioPharm logo — Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP

TC BioPharm

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP

Founded 2014 United Kingdom United Kingdom 51 employees Post Ipo Equity Total: $46.61M Biotechnology, Health Care +1

General Information

Company Name TC BioPharm
Founded Year 2014
Location United Kingdom United Kingdom +1
Employees 51
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when TC BioPharm moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TC BioPharm

TC BioPharm (Ticker: $TCBP) is a publicly traded, clinical-stage cell therapy company that was founded in 2013. The company is at the forefront of developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as pioneering gamma delta T cell therapies for the treatment of infectious diseases. With its headquarters in the United Kingdom, TC BioPharm has positioned itself as a prominent player in the biotechnology and health care industries. TC BioPharm's recent financing activity includes a £3.10M post-IPO equity investment on 06 May 2024. This signifies continued investor confidence in the company's innovative approach to combating cancer and infectious diseases. The company's growing team based in its Glasgow office, along with a diverse group of scientific advisors and partner organizations, underscores its commitment to advancing cutting-edge cell therapy solutions. Overall, TC BioPharm's focus on harnessing the potential of γδ T cells for treating cancer and infectious diseases positions it as a compelling player in the biotechnology and health care sectors, while its recent investment activity demonstrates ongoing investor interest in its advancements.

Taxonomy: Cell Therapy, CAR-T Therapy, Cancer Treatment, Gamma Delta T Cells, Clinical-Stage, Allogeneic Therapy, Immunotherapy, Regenerative Medicine, Clinical Development, Solid Tumors, Infectious Disease, Biopharmaceuticals, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 06 May 2024
Post-IPO Equity •••••• - 18 Mar 2024
Post-IPO Equity •••••• - 19 Dec 2023
Post-IPO Equity •••••• - 28 Mar 2023
Post-IPO Equity •••••• - 30 Nov 2022

View All 9 Funding Rounds

TC BioPharm Alternatives & Competitors

TC BioPharm vs
Tessa Therapeutics Ltd
Tessa Therapeutics Ltd Singapore

A clinical-stage biotech company developing autologous and allogeneic cell therapies for the treatme...

Grant
47 employees
Biotechnology, Health Care
Compare TC BioPharm vs Tessa Therapeutics Ltd
TC BioPharm vs
Matterhorn Biosciences
Matterhorn Biosciences Switzerland

M-TCR cell therapies targeting a new hallmark of cancer

Series Unknown
7 employees
Biopharma, Biotechnology
Compare TC BioPharm vs Matterhorn Biosciences
TC BioPharm vs
CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment
CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment Taiwan

Innovative BsAb Armed-T therapy platform utilizes non-viral bi-functional antibodies (BsAb) to empow...

9 employees
Also compare with: TC BioPharm vs Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology

FAQ About TC BioPharm

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP
TC BioPharm was founded in 2014.
TC BioPharm is headquartered in United Kingdom.
TC BioPharm operates in the following industries: Biotechnology, Health Care, Health and Wellness.
TC BioPharm has approximately 51 employees.
TC BioPharm has completed 9 funding rounds, raising a total of $46.61M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to TC BioPharm include Tessa Therapeutics Ltd, Matterhorn Biosciences, CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment, Stem Cell Cure India, Huasaiboman Medical Cell Biology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TC BioPharm and Tessa Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TC BioPharm and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy